[go: up one dir, main page]

MX2019004784A - Metodos de purificacion del virus adeno-asociado. - Google Patents

Metodos de purificacion del virus adeno-asociado.

Info

Publication number
MX2019004784A
MX2019004784A MX2019004784A MX2019004784A MX2019004784A MX 2019004784 A MX2019004784 A MX 2019004784A MX 2019004784 A MX2019004784 A MX 2019004784A MX 2019004784 A MX2019004784 A MX 2019004784A MX 2019004784 A MX2019004784 A MX 2019004784A
Authority
MX
Mexico
Prior art keywords
adeno
associated virus
purification methods
virus purification
methods
Prior art date
Application number
MX2019004784A
Other languages
English (en)
Inventor
Grillberger Leopold
Hasslacher Meinhard
Fiedler Christian
Kraus Barbara
Mittergradnegger Dominik
Reuberger Stefan
Bendik Marian
Schafhauser Horst
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2019004784A publication Critical patent/MX2019004784A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan en la presente métodos para producir un producto del virus adeno-asociado (AAV), métodos para purificar virus asociado con adeno, y métodos para purificar cápsides de AVV enteros de una fracción AAV concentrada que comprende cápsides AVV vacíos y cápsides de AVV enteros.
MX2019004784A 2016-11-04 2017-11-03 Metodos de purificacion del virus adeno-asociado. MX2019004784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417775P 2016-11-04 2016-11-04
PCT/US2017/059967 WO2018128688A1 (en) 2016-11-04 2017-11-03 Adeno-associated virus purification methods

Publications (1)

Publication Number Publication Date
MX2019004784A true MX2019004784A (es) 2019-08-12

Family

ID=62044944

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004784A MX2019004784A (es) 2016-11-04 2017-11-03 Metodos de purificacion del virus adeno-asociado.

Country Status (15)

Country Link
US (2) US11000561B2 (es)
EP (2) EP4234688A3 (es)
JP (1) JP7071348B2 (es)
KR (1) KR102482744B1 (es)
CN (1) CN110168081B (es)
AU (1) AU2017391164B2 (es)
CA (1) CA3040288A1 (es)
ES (1) ES2948849T3 (es)
FI (1) FI3535388T3 (es)
IL (1) IL266162B2 (es)
MX (1) MX2019004784A (es)
PL (1) PL3535388T3 (es)
PT (1) PT3535388T (es)
SG (1) SG11201903890QA (es)
WO (1) WO2018128688A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017315679B2 (en) 2016-08-23 2023-12-14 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
KR20210032984A (ko) * 2018-07-11 2021-03-25 박스알타 인코퍼레이티드 Aav 조성물
US20210082541A1 (en) * 2019-08-31 2021-03-18 Wyatt Technology Corporation Measuring attributes of a viral gene delivery vehicle sample via separation
US20220402968A1 (en) * 2019-12-12 2022-12-22 Emd Millipore Corporation Intensified virus filtration using diafiltration buffer
JP7588466B2 (ja) * 2020-01-22 2024-11-22 旭化成メディカル株式会社 パルボウイルスの生産方法
WO2021153659A1 (ja) * 2020-01-31 2021-08-05 Ａｇｃ株式会社 アデノ随伴ウイルス（ａａｖ）の定量方法
EP3868886A1 (en) * 2020-02-21 2021-08-25 Bia Separations D.O.O. A method for separation or depletion of empty aav capsids from full aav capsids
EP4114958A1 (en) 2020-02-21 2023-01-11 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
JP7526360B2 (ja) * 2020-08-18 2024-07-31 ザルトリウス ビーアイエー セパレーションズ ディー．オー．オー． マルチモーダル金属アフィニティー処理ａａｖカプシド
CN111808828B (zh) * 2020-09-14 2020-11-17 和元生物技术（上海）股份有限公司 腺相关病毒的分离纯化方法
US20250197794A1 (en) * 2020-10-14 2025-06-19 Avantor Performance Materials, Llc Membrane rupture compositions and methods of making and using same
MX2023005041A (es) * 2020-11-02 2023-05-17 Biomarin Pharm Inc Proceso para enriquecer virus adenoasociado.
US20220169991A1 (en) * 2020-12-01 2022-06-02 Global Life Sciences Solutions Usa Llc Viral vector purification apparatus and method
JP7713739B2 (ja) * 2021-04-15 2025-07-28 国立大学法人 東京大学 ウイルス粒子の製造方法
WO2022229702A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. Aav8 capsid variants with enhanced liver targeting
WO2022229703A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. New aav8 based immune escaping variants
WO2023028035A1 (en) * 2021-08-23 2023-03-02 University Of Florida Research Foundation, Incorporated Lipid enveloped recombinant aav particles for gene therapy use
GB202206123D0 (en) * 2022-04-27 2022-06-08 Cytiva Bioprocess R & D Ab A pre-screening method and a method for separating adeno-associated virus capsids

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
JPS5415417A (en) 1977-06-10 1979-02-05 Hitachi Ltd Fabrication of cast
EP0005408B1 (en) 1978-05-08 1982-12-01 Merck & Co. Inc. A process for the direct extraction of small size particles of up to 50 nm from a protein aceous liquid
US4217418A (en) 1978-05-08 1980-08-12 Merck & Co., Inc. Recovery of small particles by flow centrifugation
JPH06247995A (ja) 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル（α２−６）ラクトテトラオシルセラミド
US5688675A (en) * 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
WO1999061643A1 (en) * 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
EP1104767A1 (en) * 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
EP1255561B1 (en) 2000-02-15 2006-06-28 ID Biomedical Corporation of Quebec Proteosome influenza vaccine
AU2002348151A1 (en) * 2001-11-05 2003-05-19 Genvec, Inc. Viral vector production methods and compositions
AU2003229060A1 (en) * 2002-05-14 2003-12-02 Merck And Co., Inc. Methods of adenovirus purification
EP1608683B1 (en) 2003-04-01 2011-11-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies directed against hepatitis c virus e1e2 complex and pharmaceutical compositions
DE602004030327D1 (de) * 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
JP2007068401A (ja) 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1739801A (zh) 2004-08-27 2006-03-01 上海生物制品研究所 一种流行性感冒病毒裂解疫苗及其制备方法
RU2503719C2 (ru) 2007-05-04 2014-01-10 Бакстер Интернэшнл Инк. Способ очистки вирусов путем ультрацентрифугирования в градиенте концентрации сахара (варианты)
WO2010148143A1 (en) * 2009-06-16 2010-12-23 Genzyme Corporation Improved methods for purification of recombinant aav vectors
KR101808496B1 (ko) * 2009-07-31 2017-12-12 백스터 인터내셔널 인코포레이티드 Adamts 단백질 발현을 위한 세포 배양 배지
WO2011094198A1 (en) 2010-01-28 2011-08-04 The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
WO2011097447A2 (en) * 2010-02-04 2011-08-11 Neurologix, Inc. Production of recombinant virus
AU2014244167A1 (en) * 2013-03-13 2015-10-08 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
EP3054006A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
CN105396128A (zh) * 2015-11-11 2016-03-16 北京科兴中维生物技术有限公司 一种纯化脊髓灰质炎病毒液的方法

Also Published As

Publication number Publication date
CN110168081A (zh) 2019-08-23
AU2017391164A1 (en) 2019-05-02
US20210338752A1 (en) 2021-11-04
CA3040288A1 (en) 2018-07-12
IL266162A (en) 2019-06-30
US20190365835A1 (en) 2019-12-05
EP3535388B1 (en) 2023-05-31
EP4234688A3 (en) 2023-09-27
JP7071348B2 (ja) 2022-05-18
RU2019113381A3 (es) 2021-04-06
ES2948849T3 (es) 2023-09-20
US12246047B2 (en) 2025-03-11
IL266162B1 (en) 2023-07-01
RU2019113381A (ru) 2020-12-04
AU2017391164B2 (en) 2024-01-04
SG11201903890QA (en) 2019-05-30
CN110168081B (zh) 2024-08-16
WO2018128688A1 (en) 2018-07-12
EP4234688A2 (en) 2023-08-30
US11000561B2 (en) 2021-05-11
JP2020502997A (ja) 2020-01-30
PL3535388T3 (pl) 2023-08-14
FI3535388T3 (fi) 2023-06-14
EP3535388A1 (en) 2019-09-11
PT3535388T (pt) 2023-06-27
IL266162B2 (en) 2023-11-01
KR102482744B1 (ko) 2022-12-30
BR112019009033A2 (pt) 2019-07-09
KR20190073529A (ko) 2019-06-26

Similar Documents

Publication Publication Date Title
MX2019004784A (es) Metodos de purificacion del virus adeno-asociado.
IL263801B1 (en) Novel adeno-associated virus capsid proteins
IL275533A (en) Adeno-associated virus purification methods
MX2016009965A (es) Produccion de alta titulacion de vectores virales adenoasociados.
EP3262162A4 (en) Regulatable expression using adeno-associated virus (aav)
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
MX2017006652A (es) Vectores de virus adeno-asociado (aav) dirigidos al sistema nervioso central.
MX349601B (es) Remocion de virus contaminantes de preparaciones de aav.
EA201790630A1 (ru) Способы получения рибозидов
EP3387137A4 (en) TARGET PEPTIDES FOR LEADING ADENO ASSOCIATED VIRUSES (AAVS)
PH12018502104A1 (en) Column-based fully scalable raav manufacturing process
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EA201791216A1 (ru) Иммуномодуляторы
EA201790695A1 (ru) Иммуномодуляторы
CA2921232A1 (en) Adeno-associated virus factor viii vectors
MX387400B (es) Células de mamífero que expresan antígenos de citomegalovirus.
IL304688A (en) Production of adeno-associated virus (aav).
MY189993A (en) Process for catalytic preparation of aldehydes from olefins using monophosphite mixtures
SG10201806481XA (en) Marburg monoclonal antibodies
MX2020004014A (es) Sistema optimizado de protocolo de seguridad de cabecera.
SI3400225T1 (sl) Pentanojske kisline substituirane s pirolo-(2-3,b)pirimidin-piridini za zdravljenje okužb z virusom gripe
SA517380723B1 (ar) rHu-GCSF طريقة لتنقية
SG10201503934QA (en) Membrane-Supported Catalyst Removal In The Epoxidation of Cyclic Unsaturated C12 Compounds, For Example Cyclododecene (CDEN)
SG11201507915RA (en) Process for the purification of 1,3-butadiene from an oxidative dehydrogenation process
PH12017502386A1 (en) Methods of purification and/or viral inactivation